Having pharmacologically validated the BRCA synthetic lethality, we performed a cell panel screen covering a diverse set of tumor indications to identify potential cancer subtypes with sensitivity to MSC778 beyond BRCA1/2-mediated HRD. The gene discussed is BRCA1; the disease is cancer.